Proxy firm questions delisting plan of Fresenius Kabi

0 Comments, Be the first to comment Moneylife Digital Team | 18/04/2013 03:39 PM | The world-class oncology drug manufacturer has decided to delist its shares from the bourses at Rs130 instead of complying with SEBI's mandate of 25% public float.

Delisting offer is pursuant to the approaching deadline to meet minimum public listing norms by June end. German healthcare firm Fresenius has made a delisting offer for its Gurgaon-based pharmaceutical arm Fresenius Kabi Oncology Ltd, to acquire ...

SES says Fresenius violated Sebi guidelines on OFS sales unless it has valid and acceptable reasons Aman Malik New Delhi: Stakeholders Empowerment Services (SES), a shareholder-advisory firm, has recommended that stockholders of drug maker ...

6:00 PM Mumbai CRISIL fourth quarter net declined 15% and Essar Ports net swung to profit. Government controlled HMT soared on speculation of capital injection. IndusInd Bank fourth quarter net climbed 37.6% and MRF second quarter net jumped 40%.

Views on markets today Key benchmark indices closed flat after witnessing high intraday volatility. The barometer index, the S&P BSE Sensex, was provisionally down 9.76 points or 0.05%, off close to 135 points from the day's high and up about 60 ...

6:00 PM Mumbai Crompton Greaves secured contract worth $60 million from Iraq. GAIL plans to sell its 4.6% stake in China Gas Holdings. HCL Technologies third quarter jumped 7.8%. Oil India plans to raise $400 million. TCS fourth quarter net rose 3% ...

After a choppy session, the markets closed on a flat note, weighed down by selling in oil & gas and IT counters. The Sensex closed down 14 points at 18,731 while the Nifty closed unchanged at 5,688.The broader markets, however, managed to retain some of its gains as the mid and small cap indices closed up 0.2-0.3%, outperforming the BSE benchmark index which closed flat with a negative bias.Meanwhile, India's current account deficit could ease to around 3% in the current fiscal year from ...

SC rejects Novartis's patent plea for Glivec, says it does not meet any standard of novelty or inventiveness Vidya Krishnan | C.H. Unnikrishnan Novartis AG headquarters in Basel, Switzerland. Also Read Updated: Tue, Apr 02 2013. 12 54 AM IST New ...